Dexilant Safety in Breastfeeding
Dexilant (dexlansoprazole) can be used during breastfeeding, though with caution due to limited human data. The FDA drug label explicitly states that there is no information regarding the presence of dexlansoprazole in human milk, effects on the breastfed infant, or effects on milk production 1.
Key Considerations
What the Evidence Shows
The FDA label provides the most direct guidance: "There is no information regarding the presence of dexlansoprazole in human milk, the effects on the breastfed infant, or the effects on milk production" 1. However, the label notes that lansoprazole (the racemic mixture from which dexlansoprazole is derived) and its metabolites are present in rat milk 1.
The FDA recommends that "the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for DEXILANT and any potential adverse effects on the breastfed child from DEXILANT or from the underlying maternal condition" 1.
Clinical Decision-Making Algorithm
When a breastfeeding mother requires acid suppression therapy:
- Assess clinical necessity: Determine if PPI therapy is truly required versus alternatives like H2-receptor antagonists or lifestyle modifications
- Consider the infant's age: Younger infants (especially neonates) have immature drug metabolism and may be at higher theoretical risk
- Monitor the infant: Watch for gastrointestinal symptoms, feeding difficulties, or unusual fussiness
- Use the lowest effective dose: If Dexilant is chosen, use 30 mg rather than 60 mg when clinically appropriate
Important Caveats
Dexilant is NOT recommended in children under 2 years of age due to potential harm 1. While this refers to direct administration to children, it raises theoretical concerns about exposure through breast milk, particularly in very young infants.
The lack of human lactation data means we cannot definitively quantify infant exposure or rule out adverse effects. Animal data showing presence in rat milk suggests some degree of transfer is biologically plausible 1.
Practical Approach
Given the absence of human safety data, if acid suppression is medically necessary during breastfeeding:
- Prefer alternative PPIs with more lactation data (such as omeprazole or lansoprazole, which have been more extensively studied in breastfeeding)
- If Dexilant is specifically indicated (e.g., due to superior symptom control or insurance coverage), it can be used with informed consent and infant monitoring
- Document the discussion about unknown risks versus benefits of continued breastfeeding
- Avoid use in mothers of very young infants (under 2 months) when possible, given the pediatric contraindication in children under 2 years
The decision ultimately requires balancing the well-established benefits of breastfeeding against theoretical but unquantified risks from a medication with no human lactation data 1.